Quantitative and qualitative aspects of radiolocalization in colon cancer patients of intravenously administered MAb B72.3

Monoclonal antibody (MAb) B72.3 has been previously shown, by in vitro assays, to have a high degree of specificity for carcinomas of the colon, ovary and breast versus normal adult tissues. B72.3 IgG was labelled with 131I and injected i.v. into 20 patients with known or suspected colorectal cancer. All patients subsequently underwent surgical exploration, with tumor and selected normal tissues removed for staging purposes. The selective localization of 131I‐MAb B72.3 IgG was demonstrated in biodistribution studies in which the % ID/g of each tumor was compared with that of the normal tissues, thus providing a relative RI for each lesion. Of the tumor lesions, 70% (99/142) had an RI of at least 3 (i.e., 3 times greater uptake per gram than normal tissues), and 31% of the tumor lesions had RIs of over 10. Only 12 of 210 (6%) histologically normal tissues had RIs of > 3; either these tissues were adjacent to or draining tumor masses or, as in the case of 2 patients, the high RI values were apparently due to deposition of immune complexes in the splenic tissues. Several parameters were studied to determine factors that might influence MAb localization. Whereas tumors of all histologic types localized the MAb, 31% of the well‐differentiated mucinous carcinomas displayed tumor‐to‐normal ratios greater than 10, while less than 5% of the lesions of other tumor types demonstrated similar localization. The expression of the antigen (TAG‐72) detected by MAb B72.3 in these tumors, as studied by immunohistochemical techniques using tissue sections, did not always correlate with the outcome of the MAb distribution. No differences in MAb uptake were observed among the carcinoma lesions from numerous anatomic locations, demonstrating the ability of i.v. administered B72.3 to reach all the tumor sites. Furthermore, autoradiographic studies of tumors showed good penetration of the MAb into the medial areas of the tumors, regardless of their size.

[1]  J. Schlom,et al.  Differential reactivity of monoclonal antibodies with human colon adenocarcinomas and adenomas , 1983, International journal of cancer.

[2]  A. Thor,et al.  Identification of adenocarcinoma in cytospin preparations of effusions using monoclonal antibody B72.3. , 1986, American journal of clinical pathology.

[3]  S. Hsu,et al.  Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. , 1981, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[4]  M. A. Sattler,et al.  Monoclonal antibody immunoradiometric assay for an antigenic determinant (CA 72) on a novel pancarcinoma antigen (TAG‐72) , 1986, International journal of cancer.

[5]  M. Herlyn,et al.  Tumor localization in patients by radiolabeled monoclonal antibodies against colon carcinoma. , 1983, Cancer research.

[6]  R. Mariani-Costantini,et al.  A monoclonal antibody (B72.3) defines patterns of distribution of a novel tumor‐associated antigen in human mammary carcinoma cell populations , 1982, International journal of cancer.

[7]  P. Hand,et al.  A spectrum of monoclonal antibodies reactive with human mammary tumor cells. , 1981, Proceedings of the National Academy of Sciences of the United States of America.

[8]  J. Schlom,et al.  Use of monoclonal antibodies to human breast‐tumor‐associated antigens in fine‐needle aspirate cytology , 1986, International journal of cancer.

[9]  A. Thor,et al.  Use of a monoclonal antibody (B72.3) as an immunocytochemical adjunct to diagnosis of adenocarcinoma in human effusions. , 1985, Cancer research.

[10]  S. Larson,et al.  Prolonged binding of a radiolabeled monoclonal antibody (B72.3) used for the in situ radioimmunodetection of human colon carcinoma xenografts. , 1984, Cancer research.

[11]  J. Douillard,et al.  Immunoscintigraphy of colon carcinoma. , 1984, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[12]  A. Thor,et al.  Tumor-associated glycoprotein (TAG-72) in ovarian carcinomas defined by monoclonal antibody B72.3. , 1986, Journal of the National Cancer Institute.

[13]  J. Schlom,et al.  A radioimmunoassay for the detection of a human tumor‐associated glycoprotein (tag‐72) using monoclonal antibody B72.3 , 1986, International journal of cancer.

[14]  J. Schlom,et al.  Analysis of a human tumor-associated glycoprotein (TAG-72) identified by monoclonal antibody B72.3. , 1986, Cancer research.

[15]  S. Larson,et al.  Radioimmunoscintigraphy of human colon cancer xenografts in mice with radioiodinated monoclonal antibody B72.3. , 1984, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[16]  A. Thor,et al.  Distribution of oncofetal antigen tumor-associated glycoprotein-72 defined by monoclonal antibody B72.3. , 1986, Cancer research.

[17]  R. W. Baldwin,et al.  The use of monoclonal antibody 791T/36 in the immunoscintigraphy of primary and metastatic carcinoma of the breast. , 1984, Clinical oncology.

[18]  S. Larson,et al.  Imaging of melanoma with L-131-labeled monoclonal antibodies. , 1983, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[19]  C. Mulhern,et al.  Metastatic colon carcinoma detected with radiolabeled F(ab')2 monoclonal antibody fragments. , 1983, Radiology.

[20]  M. Forni,et al.  Use of radiolabelled monoclonal anti-CEA antibodies for the detection of human carcinomas by external photoscanning and tomoscintigraphy. , 1981, Immunology today.